Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -24.02% is 51% above its 5-year average of -49.01%, near the high end of its 5-year range (-458.00%–-6.00%).
As of the fiscal period ended Tuesday, June 30, 2026. 16.94% above its 12-month average of -28.92%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -24.02%.
RETURN ON EQUITY (ROE)
-24.02%
RETURN ON EQUITY (ROE) AVG TTM
-28.92%
RETURN ON EQUITY (ROE) AVG 3Y
-51.28%
RETURN ON EQUITY (ROE) AVG 5Y
-49.01%
RETURN ON EQUITY (ROE) AVG 10Y
-48.13%
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+16.94%
CURRENT VS 3Y AVG
+53.16%
CURRENT VS 5Y AVG
+50.99%
CURRENT VS 10Y AVG
+50.09%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.21%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
+40.26%
vs the sector median at left
Corvus Pharmaceuticals, Inc.
Market Cap
$892.19M
Return on Equity (ROE)
-24.02%
TTM Avg
-28.92%
3Y Avg
-51.28%
5Y Avg
-49.01%
Market Cap
$898.28M
Return on Equity (ROE)
23.86%
TTM Avg
-5.16%
3Y Avg
-37.28%
5Y Avg
-22.23%
Market Cap
$901.76M
Return on Equity (ROE)
59.16%
TTM Avg
-57.78%
3Y Avg
-58.75%
5Y Avg
-57.09%
Market Cap
$914.51M
Return on Equity (ROE)
5.94%
TTM Avg
5.38%
3Y Avg
4.71%
5Y Avg
4.13%
Market Cap
$865.07M
Return on Equity (ROE)
-33.06%
TTM Avg
-24.59%
3Y Avg
-41.17%
5Y Avg
-18.72%
Market Cap
$933.77M
Return on Equity (ROE)
-51.43%
TTM Avg
-27.77%
3Y Avg
3.43%
5Y Avg
3.43%
Market Cap
$849.39M
Return on Equity (ROE)
-97.08%
TTM Avg
-96.94%
3Y Avg
-22.72%
5Y Avg
-22.72%
Market Cap
$842.88M
Return on Equity (ROE)
-28.46%
TTM Avg
-48.75%
3Y Avg
-33.66%
5Y Avg
-33.66%
Market Cap
$841.07M
Return on Equity (ROE)
-59.07%
TTM Avg
-63.84%
3Y Avg
-29.19%
5Y Avg
-3.25%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Corvus Pharmaceuticals, Inc. (CRVS) | $892.19M | -24.02% | -28.92% | -51.28% | -49.01% |
| Bioventus Inc. (BVS)vs › | $898.28M | 23.86% | -5.16% | -37.28% | -22.23% |
| Arbutus Biopharma Corp (ABUS)vs › | $901.76M | 59.16% | -57.78% | -58.75% | -57.09% |
| HealthStream, Inc. (HSTM)vs › | $914.51M | 5.94% | 5.38% | 4.71% | 4.13% |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $865.07M | -33.06% | -24.59% | -41.17% | -18.72% |
| CeriBell, Inc. (CBLL)vs › | $933.77M | -51.43% | -27.77% | 3.43% | 3.43% |
| Alumis Inc. (ALMS)vs › | $849.39M | -97.08% | -96.94% | -22.72% | -22.72% |
| Beta Bionics, Inc. (BBNX)vs › | $842.88M | -28.46% | -48.75% | -33.66% | -33.66% |
| QuidelOrtho Corporation (QDEL)vs › | $841.07M | -59.07% | -63.84% | -29.19% | -3.25% |
| Jade Biosciences, Inc. (JBIO)vs › | $836.04M | -34.83% | -64.71% | -59.77% | -96.53% |
ROE
-24.0%
ROA
-22.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -24.02% |
| 2026-03-31 | -18.35% |
| 2025-12-31 | -24.97% |
| 2025-09-30 | -21.01% |
| 2025-06-30 | -56.26% |
| 2025-03-31 | -83.93% |
| 2024-12-31 | -191.27% |
| 2024-09-30 | -458.00% |
| 2024-06-30 | -44.15% |
| 2024-03-31 | -74.50% |
| 2023-12-31 | -69.87% |
| 2023-09-30 | -68.17% |
| 2023-06-30 | -78.86% |
| 2023-03-31 | -83.66% |
| 2022-12-31 | -73.61% |
| 2022-09-30 | -62.97% |
| 2022-06-30 | -45.49% |
| 2022-03-31 | -44.54% |
| 2021-12-31 | -44.50% |
| 2021-09-30 | -6.33% |
| 2021-06-30 | -6.00% |
| 2021-03-31 | -4.92% |
| 2020-12-31 | -8.31% |
| 2020-09-30 | -104.81% |
| 2020-06-30 | -89.69% |
| 2020-03-31 | -79.89% |
| 2019-12-31 | -65.63% |
| 2019-09-30 | -57.37% |
| 2019-06-30 | -50.89% |
| 2019-03-31 | -43.97% |
| 2018-12-31 | -42.54% |
| 2018-09-30 | -40.69% |
| 2018-06-30 | -39.70% |
| 2018-03-31 | -39.30% |
| 2017-12-31 | -65.61% |
| 2017-09-30 | -58.48% |
| 2017-06-30 | -50.01% |
| 2017-03-31 | -38.96% |
| 2016-12-31 | -27.39% |
| 2016-09-30 | -21.92% |
| 2016-06-30 | -15.91% |
| 2016-03-31 | -23.45% |
